Turning Point Therapeutics, Inc.
TPTXN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Sep 30, 2026
28wMarket Overview
Stock performance and key metrics
TPTX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oral repotrectinib (TPX-0005) | Phase 2 | Locally Advanced Solid Tumors | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply